linjc16/ctgov huggingface dataset:
Traditional Versus ScvO2 Guided Perioperative Fluid Therapy

Study Overview
=================
Brief Summary
-----------------
Perioperative goal directed fluid therapy by means of an esophageal doppler has been shown to reduce morbidity and length of stay. In this study patients undergoing elective bowel surgery will be randomised to traditional fluid therapy with crystalloids versus fluid boluses guided by central venous oxygen saturation. The primary outcome will be complications after surgery.

Official Title
-----------------
Randomized Clinical Study of Traditional Versus ScvO2 Guided Perioperative Fluid Therapy

Conditions
-----------------
Perioperative Care

Intervention / Treatment
-----------------
* Procedure: Intravenous fluid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective bowel surgery, Able to give informed consent Exclusion Criteria: Coagulation defect, Renal failure, Valvular stenosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 2<br>Fluid therapy guided by blood pressure and urine production | Procedure: Intravenous fluid<br>* The same intravenous fluids will be used in both arms but the volume will be different<br>|
| Experimental: 1<br>ScvO2 guided fluid therapy | Procedure: Intravenous fluid<br>* The same intravenous fluids will be used in both arms but the volume will be different<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative morbidity |  | postoperative day 30 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum creatinine |  | postoperative day 3 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
central venous saturation, bowel surgery, morbidity, intravenous infusions
Investigating Kinematic and Electromyographic Changes After SCI and Their Relation to Clinical and Functional Outcome

Study Overview
=================
Brief Summary
-----------------
The study aims at discerning specific gait patterns and elucidating locomotor control of spinal cord injured patients in order to find sensitive kinematic and electromyographic outcome measures that are able to reveal information on underlying mechanisms of normal and aberrant gait control and its recovery over time. These measures may also be used to compare the outcome across different neurological disorders.

Conditions
-----------------
Spinal Cord Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients: We will monitor patients who were admitted to the Spinal Cord Injury Center of the University Hospital Balgrist. We will record patients with various aetiologies, grades of impairment and types of spinal cord lesions. Patients need to have minimal voluntary motor capacities: the motor scores of the key muscles according to the ASIA classification (www.asia-spinalinjury.org) should be at least 3 for extensor muscles and 2 for flexor muscles. Written informed consent is required. Control subjects: Healthy subjects, written informed consent. Exclusion Criteria: Patients: Comorbidities which influence or inhibit gait or upper-limb motion (e.g. peripheral nerve lesions). Orthostatic problems that greatly impair upright body position. Mental illness, cognitive impairments. Control subjects: neurologic disease, walking disabilities, mental illness, cognitive impairments
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SCI patients<br> | |
| Healthy subjects<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of gait kinematics after spinal cord injury over one year |  | 1) very acute: 0 - 14 days after injury; 2) acute I: 2 - 4 weeks post-injury; 3) acute II: 4 - 12 weeks post-injury; 4) acute III: 12 - 24 weeks post-injury; 5) chronic: 24 - 48 weeks post-injury |
Aromatherapy for Anxiety Among Children With Autism Spectrum Disorder

Study Overview
=================
Brief Summary
-----------------
This study evaluated the use of bergamot aromatherapy in the treatment of anxiety in a medical office setting among children who are diagnosed with an autism spectrum disorder. H

Detailed Description
-----------------
Bergamot aromatherapy relieves anxiety in adult populations but has not been tested in a pediatric population with autism spectrum disorder. Because autism spectrum disorders often include hypersensitivity to sensory experiences, the use of essential oils in this population should be evaluated.

Official Title
-----------------
Bergamot Aromatherapy for Anxiety in a Medical Office Among Children With Autism Spectrum Disorder: A Randomized, Controlled Trial

Conditions
-----------------
Anxiety, Autism Spectrum Disorder

Intervention / Treatment
-----------------
* Other: Bergamot Aromatherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between 6-11 years of age Diagnosed with an autism spectrum disorder Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bergamot Aromatherapy<br>Patients in this group inhaled bergamot essential oil for 15 minutes at the start of their medical office visit. | Other: Bergamot Aromatherapy<br>* Patients in this group inhaled bergamot essential oil for 15 minutes.<br>|
| No Intervention: Control<br>Patients in this group did not experience an intervention. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline State Trait Anxiety Inventory for Children | Self reported anxiety survey measuring state anxiety in children through 20 questions with a score ranging from 0-60 with higher scores representing higher anxiety. | baseline and after the 15 minute intervention | 
| Change from baseline in Blood Pressure | Routine blood pressure measurement | baseline and after the 15 minute intervention | 
| Change from baseline in Heart Rate | Routine heart rate measurement | baseline and after the 15 minute intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aromatherapy, Essential Oils, Children
Stem Cell Therapy in Muscular Dystrophy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to analyze the effect of autologous bone marrow mononuclear cells in muscular dystrophy.

Official Title
-----------------
Role of Autologous Mononuclear Cell Therapy in Muscular Dystrophy

Conditions
-----------------
Muscular Dystrophy

Intervention / Treatment
-----------------
* Biological: Stem Cell


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age group of 6 months and above muscular dystrophy diagnosed on the basis of clinical presentation Exclusion Criteria: presence of respiratory distress presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus malignancies acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction < 30% pregnancy or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Stem Cell<br>Bone marrow mononuclear cell transplantation | Biological: Stem Cell<br>* Intrathecal Autologous bone marrow mononuclear cell transplantation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Manual Muscle Testing |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Muscular Dystrophy, Autologous Mononuclear cell therapy, Stem Cell
Increasing Physical Activity Levels in Low-Income Women

Study Overview
=================
Brief Summary
-----------------
Regular physical activity is important for good health. Women, particularly women with low incomes, have many personal barriers to regular physical activity. The purpose of this study is to reduce environmental barriers to physical activity for women in two specific low-income neighborhoods (in Louisville, KY) by providing opportunities for safe physical activity and addressing barriers such as lack of child care. Two groups of women will have pretest information (cholesterol, blood sugar, blood pressure, percent body fat, height, weight, waist and hip measurements) collected and the same information 6 months later at post-test. One group will have access to multiple physical activity opportunities in their neighborhood and at the neighborhood community center. An advanced registered nurse practitioner will facilitate the activity opportunities. The groups will be compared on their pretest and post-test information to see if the group with the physical activity opportunities has increased physical activity as measured by pedometer and self-report questionnaire, and to see if there are changes in the measures tested at pre and post (measures that may be improved by regular physical activity).

Official Title
-----------------
Environmental Approaches to Reducing Obesity: Increasing Physical Activity Levels in Low-Income Women

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Behavioral: Physical activity opportunities for low-income women


Participation Criteria
=================
Eligibility Criteria
-----------------
live in one of two specific low-income neighborhoods in Louisville, KY

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Physical activity opportunities for low-income women|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Ambulatory Assessment of Motor State in Patients With Parkinson's Disease in Real Daily Life

Study Overview
=================
Brief Summary
-----------------
Patients with Parkinson's disease (PD) suffer from motor fluctuations and levodopa induced dyskinesia. The prupose of this study is to evaluate the effect of an automatic system to assess the motor state of PD patients in real daily life. Movements and postures are assessed using 6 accelerometers attached to the the most affected wrist, trunk, both upper legs and both upper arms. Patients wear the system for two days and keep an own diary of their motor state

Conditions
-----------------
Parkinson's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with parkinson's disease with motor fluctuations and dyskinesias Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
InPractice Survey on the Treatment of Hypercholesterolemia

Study Overview
=================
Brief Summary
-----------------
This is a multi-centre survey of patients who are currently on lipid-lowering pharmacological treatment. Data collection for each patient will take place at one visit.

Official Title
-----------------
InPractice Survey on the Treatment of Hypercholesterolemia

Conditions
-----------------
Hypercholesterolemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject must be 18 years of age or older of either sex. Subject is on lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. Exclusion Criteria: Subjects who are unwilling or unable to provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dyslipidemia, in practice survey, Vietnam
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Official Title
-----------------
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder

Conditions
-----------------
Generalized Anxiety Disorder

Intervention / Treatment
-----------------
* Drug: Quetiapine fumarate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has a documented clinical diagnosis of Generalized Anxiety Disorder. Be able to understand and comply with the requirements of the study. Able to understand and provide written informed consent Exclusion Criteria: Patients (female) must not be pregnant or lactating Current or past diagnosis of stroke or transient ischemic attack (TIA).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Quetiapine fumarate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from randomization in the HAM-A total score at Day 57 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from randomization in CGI-S score at Day 57 |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GAD, anxiety
Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.

Study Overview
=================
Brief Summary
-----------------
Compare UVA-1 phototherapy treatment to topical steroid treatment in subjects with morphea.

Official Title
-----------------
A Prospective, Open Label Trial of High Dose UVA-1, 3x/Week or Medium Dose UVA-1, 3x/Week vs. Fluocinonide 0.05% Cream Treatment of Morphea

Conditions
-----------------
Symmetric Limited Morphea

Intervention / Treatment
-----------------
* Other: Medium Dose UVA-1
* Other: High Dose UVA-1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female subjects 18 years of age or older. Symmetric limited morphea. Exclusion Criteria: Known sensitivity to fluocinonide 0.05% cream. Clinical evidence of superinfected skin. Immunocompromised state (including previously documented HIV). Generalized Scleroderma. Previous history of skin cancer. Non-English speaking subjects.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Medium Dose UVA-1<br>Medium dose (60 J/cm2) UVA-1 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream to another morphea plaque twice daily for twelve weeks. | Other: Medium Dose UVA-1<br>* UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.<br>|
| Active Comparator: High Dose UVA-1<br>High dose UVA-1 treatment 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream twice daily for 12 weeks to another morphea plaque. | Other: High Dose UVA-1<br>* High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of UVA-1 treatment vs. topical steroid. |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Morphea, Plaque morphea, Localized Scleroderma
Optimization of an Automated Ultrasound Cardiac Guidance Tool

Study Overview
=================
Brief Summary
-----------------
Open-label, single-arm, prospective study. Subjects will undergo one session of 2D Transthoracic Echocardiogram (2D-TTE) ultrasound. The ultrasound will be performed by a trained sonographer.

Detailed Description
-----------------
The study will use a commercially available handheld imaging device (Philips Lumify transducer). Primary Objective: To acquire images of multiple transducer position, trajectories, and views, at different acoustic windows for capturing images and location relative to body and probe positions.

Official Title
-----------------
Optimization of an Automated Ultrasound Cardiac Guidance Tool

Conditions
-----------------
Ultrasound Therapy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years and above. Patients able to understand, read and sign the informed consent Patient willing to answer a short questionnaire Exclusion Criteria: Pregnancy(females of childbearing potential will be tested with a urine pregnancy test prior to their inclusion in the study) Not willing or not able to sign an inform consent Physical limitation to maneuvering the probe on the body Unable to lie flat for study Patients experiencing a known or suspected acute cardiac event Patients with severe chest wall abnormalities Patients who have undergone pneumonectomy Patients whose anatomy does not lend itself to echocardiography

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ACCURACY- Optimization of an automated ultrasound cardiac guidance tool. | To acquire images from different transducer positions, trajectories, and views, at different acoustic windows for capturing images and location relative to body and probe. This study is designed to capture data for the training of the UltraSight Guidance software AI models. The obtained data will not be anlyzed for statistical purposes but will only be used for the algorithm development based on the technician movements recording, with no reference to images quality or medical utilization. | 1 year |
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder

Study Overview
=================
Brief Summary
-----------------
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

Detailed Description
-----------------
The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to bipolar disorder

Official Title
-----------------
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder

Conditions
-----------------
Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder, Bipolar Type I Disorder, Bipolar Disorder Mild, Bipolar Disorder Moderate, Bipolar Disorder Severe

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study a. May be signed by parent or legal guardian in the case of minor or adult unable to provide consent Male or female of all ages. Greater than seven endorsements on the bipolar disorder questionnaire. Exclusion Criteria: Refusal to sign informed consent form History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy. Postoperative stoma, ostomy, or ileoanal pouch Participation in any experimental drug protocol within the past 12 weeks Treatment with total parenteral nutrition
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Bipolar Disorder<br>Patients with bipolar disorder | Other: No intervention<br>* There is no intervention for this study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing | Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized with bipolar disorder | Three years |